ELIQUIS
As listed in the register: ELIQUIS 2 mg, granulés enrobés en sachet
2 mg · granulés enrobé
- Prescription only
- Active substance
- Apixaban
- Made by
- BRISTOL-MYERS SQUIBB / PFIZER EEIG (IRLANDE)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (apixaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Apixaban is a selective inhibitor of FXa.
It does not require antithrombin III for antithrombotic activity.
Apixaban is metabolized mainly via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2.
Apixaban is eliminated in both urine and feces.
Food does not affect the bioavailability of apixaban.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-02-03
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (apixaban). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.
- ELIQUIS is contraindicated in patients with the following conditions: Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1) ] Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see Adverse Reactions (6.1) ] Active pathological bleeding (4) Severe hypersensitivity to ELIQUIS (4)
Most common adverse reactions (>1%) are related to bleeding.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
BulgariaNo exact match for this strength and form
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
Details
| Made by | BRISTOL-MYERS SQUIBB / PFIZER EEIG (IRLANDE) |
|---|---|
| Active substance | Apixaban |
| Strength | 2 mg |
| Form | granulés enrobé |
| Route | orale |
| Dispensing (as stated by the register) | liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/11/691 |
| Name in the register | ELIQUIS 2 mg, granulés enrobés en sachet |
| Packs | 28 sachet(s) aluminium avec fermeture de sécurité |
| CIS | 61425336 |
| CIP13 | 3400930302002 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
6 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.